BF
CTIC

BOK Financial’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

BOK Financial’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,500
Closed -$6K – 943
2016
Q4 		$6K Hold
1,500
– – ﹤0.01% 880
2016
Q3 		$6K Buy
+1,500
New +$5.46K ﹤0.01% 875

Other funds holding CTIC

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $18.2B AUM 22.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BOK Financial's CTIC Position: Q1 2017 in Review

BOK Financial sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q1 2017, closing a stake of 1,500 shares — an estimated $6K sold.

BOK Financial first reported a position in CTIC in Q3 2016 and held it in 2 quarters. The position peaked at $6K in Q4 2016. 47 funds tracked by Wall St. Rank hold CTIC as of Q1 2017.

  • BOK Financial reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q1 2017 after selling out during the quarter.
  • BOK Financial sold 1,500 CTI BioPharma Corp. (DE) Common Stock shares in Q1 2017, an estimated $6K.
  • BOK Financial first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q3 2016 and held it in 2 quarters.
  • BOK Financial's CTI BioPharma Corp. (DE) Common Stock position peaked at $6K in Q4 2016.
  • 47 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q1 2017.

Based on BOK Financial's 13F filing for Q1 2017, filed 15 May 2017.